InvestorsHub Logo
Followers 8
Posts 2087
Boards Moderated 0
Alias Born 08/09/2003

Re: None

Friday, 04/07/2017 2:35:31 PM

Friday, April 07, 2017 2:35:31 PM

Post# of 796
Progenics (NASDAQ:PGNX) has declined about 7% despite meeting the primary endpoint in the Phase 2b results for Azedra in pheochromocytoma released Thursday. This is unusual given the results and management's stated plans to file an NDA by mid-year.
https://seekingalpha.com/article/4061076-watch-q2-upcoming-healthcare-data-releases